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0022-2836/$ - see front matter © 2011 EIn the biosynthesis of the clinically important antibiotic erythromycin D, the
glycosyltransferase (GT) EryCIII, in concert with its partner EryCII, attaches
a nucleotide-activated sugar to the macrolide scaffold with high specificity.
To understand the role of EryCII, we have determined the crystal structure
of the EryCIII·EryCII complex at 3.1 Å resolution. The structure reveals a
heterotetramer with a distinctive, elongated quaternary organization. The
EryCIII subunits form an extensive self-complementary dimer interface at
the center of the complex, and the EryCII subunits lie on the periphery.
EryCII binds in the vicinity of the putative macrolide binding site of EryCIII
but does not make direct interactions with this site. Our biophysical and
enzymatic data support a model in which EryCII stabilizes EryCIII and also
functions as an allosteric activator of the GT.
© 2011 Elsevier Ltd. All rights reserved.Introduction
Streptomyces and related filamentous bacteria
produce a large number of structurally diverse and
clinically valuable natural products, many of which
require the attachment of specific deoxyhexose
residues for their biological activity.1 Recent ad-
vances in the cloning and analysis of biosynthetic
gene clusters for numerous aminoglycosides, poly-
ketides and nonribosomal peptides have revealed
the close mechanistic similarities in the pathways
that lead to various activated deoxysugars and their
subsequent attachment to the appropriate aglycone,
catalyzed by specific glycosyltransferases (GTs).ss: mcm35@cam.ac.uk.
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lsevier Ltd. All rights reserveThis in turn has led to the development of methods
for the manipulation of such pathways to obtain
novel altered natural products differing in their
glycosylation status and pattern. This strategy,
known as glycodiversification or glycosylation
engineering,2,3 is crucially dependent upon the
specificity of GTs and the extent to which their
specificity can be altered and expanded.
A number of GTs involved in natural product
biosynthesis have been structurally characterized,
including GtfB, which transfers glucose from
UDP-glucose to the aglycone of the glycopeptide
vancomycin;4 the deoxyaminohexose transferases
GtfA and GtfD from, respectively, the pathways
to chloreremomycin and vancomycin;5,6 and a
productive chimeric glycopeptide GT.7 Other struc-
tures solved include AviGT4 in avilamycin A
biosynthesis,8 UrdGT2 in urdamycin A biosynthesis9
and CalG3 in calicheamicin biosynthesis.10 Also, the
structures of two other GTs involved in antibiotic
export and resistance have been reported.11 All of
these belong to the GT-B structural superfamily ofd.
93EryCIII in Complex with EryCIIGTs, consisting of two domains, each adopting a
Rossmann-like α/β fold, in which the N-terminal
domain contains the acceptor binding site and the C-
terminal domain encompasses the nucleotide dispho-
spho-sugar (NDP-sugar) binding site, and catalysis
occurs at the interface between them.
Macrolide polyketides, which target protein bio-
synthesis and are indispensable, clinically used
antibiotics, are a particularly important prospective
target for glycosylation engineering, but structural
information is lacking. Moreover, for a significant
number of macrolide and aromatic biosynthetic
GTs, the activity of the GT requires a helper protein
whose function is still obscure. This dependence was
demonstrated in vitro for the GT DesVII, which
catalyzes the attachment of TDP-D-desosamine to
the 14-membered macrocyclic aglycone in the bio-
synthesis of pikromycin in Streptomyces venezuelae,
andwhose activity was found to be dependent on the
protein DesVIII.12 The auxiliary protein shows
significant sequence similarity to cytochrome P450
but lacks the essential cysteine residue that coordi-
nates the heme iron. Since then, at least 12 other GTs
have been identified that appear to function in this
way. For example, the in vitro activity of the GT
EryCIII, which produces erythromycin D (3) using
TDP-D-desosamine (2) and 3-α-mycarosylerythrono-
lide B (MycEB) (1) as substrates (see Fig. 1), was
enhanced by the addition of its auxiliary protein
EryCII.13 Once exposed to EryCII, the activity of
EryCIII was reportedly retained after subsequent
removal of the auxiliary protein. Itwas suggested that
the auxiliary protein permits correct folding of
EryCIII into an active form but does not bind tightly
and does not participate in catalysis.13 In vitro studies
of the GT/helper pair AknS/AknT in aclacinomycin
biosynthesis showed both partners to be readily
soluble recombinant proteins when separately
expressed, and AknT stimulated the glycosylation
activity (using a model sugar) of AknS, but theseHO
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Fig. 1. Biosynthesis of erythromycin D (3) from the su
GT-auxiliary protein pair EryCIII·EryCII.partners likewise showed no evidence for stable
complex formation.14 In contrast, reinvestigation of
the DesVII/DesVIII pair has shown that the two
proteins may associate tightly with 1:1 stoichiometry,
and it has been suggested that the apparently
autonomous activity of a GT after subsequent
removal of the activator reflects the continued
undetected presence of residual activator.15 It is
essential to clarify the nature of the GT/helper
protein interaction to aid rational engineering of
these GTs. We report here the purification from
recombinant Escherichia coli of a stable tetrameric
complex of EryCIII and EryCII and the solution of
the crystal structure of this complex, providing to
our knowledge the first structure for any macrolide
biosynthetic GT. The structural insights obtained
help to rationalize the role of EryCII and of
homologous auxiliary proteins in macrolide and
aromatic polyketide antibiotic biosynthesis and
should accelerate protein engineering efforts aimed
at production of novel macrolides.Results
Streptomyces chaperones increase the
solubility of actinomycete GTs in E. coli
The expression of EryCIII in E. coli BL21 (DE3)
codon plus RP cells yielded insoluble protein.
Co-expression with the E. coli chaperonins GroEL
and GroES yielded some soluble protein as reported
previously,16 but purification was compromised
by contaminating GroEL and GroES. In contrast,
co-expression with the Streptomyces coelicolor cha-
peronins GroEL1, GroES and GroEL217 produced
soluble protein (Supplementary Fig. S2a) that could
be purified to homogeneity. Purified EryCIII was
analyzed by mass spectrometry, and a mass ofO
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Fig. 2. EryCII is necessary for EryCIII activity. Electro-
spray ionization-LC-MS analysis of the activity of co-
expressed EryCIII·EryCII in cell-free extracts. Total ion
count (TIC) of an ethyl acetate extract of the GT activity
assay (a). Ion trace (m/z=569) of [M+Na+]+ of MycEB
(b) and (c) ion trace (m/z=704) of [M+H]+ of the product
erythromycin D. (d) Plot of peak areas of the erythro-
mycin D product for the control (pET28) and extracts in
which only EryCII or EryCIII were expressed are shown.
The activity of a mixture of individually expressed
EryCIII and EryCII is almost the same as that obtained
by co-expression (∗).
94 EryCIII in Complex with EryCII47,961 Da was obtained consistent with the loss of
the N-terminal methionine residue (Supplementary
Fig. S2b).
EryCII is required for catalysis by EryCIII
Purified EryCIII was used for in vitro glycosyla-
tion assays as described previously,13 but the
enzyme was inactive under all conditions tried. To
confirm that added EryCII could activate the GT
activity of EryCIII, we performed assays using E. coli
cell-free extracts. Analysis of enzyme activity relied
on electrospray mass spectrometric detection of the(b)(a)
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EryCIII⋅Erysubstrate MycEB and the product erythromycin D,
which show characteristic m/z peaks at 569[M+
Na]+ and 704[M+H]+, respectively. In Fig. 2a, a
typical result from liquid chromatography com-
bined with mass spectrometry (LC-MS) for the
extract containing co-expressed EryCIII and EryCII
is shown, and Fig. 2b summarizes these results. The
percentage conversion for co-expressed EryCIII and
EryCII, calculated from integration of the peaks on
the HPLC chromatogram for both substrate and
product, was 50–60%. When separate EryCIII- and
EryCII-containing extracts were combined, the GT
activity of EryCIII was restored, confirming as
expected that EryCII is required by EryCIII. The
control extract derived from cells transformed with
pET28 only had no GT activity. However, the extract
containing EryCII alone did have (low) enzymatic
activity, suggesting that the auxiliary protein may
be capable of activating endogenous GTs in E. coli.
EryCII stabilizes EryCIII
Figure 3a shows the experimental sedimentation
velocity profiles of EryCIII and the co-expressed
EryCIII·EryCII complex. Strikingly, the sedimenta-
tion coefficient distribution, c(S), for purified EryCIII
alone has multiple peaks (2.44 S, 3.85 S, 5.07 S, 6.07 S,
6.88 S, 7.89 S, 9.10 S and 10.11 S), which correspond
to monomeric EryCIII (2.44 S) and to various
oligomeric forms. In contrast, the c(S) distribution
for co-expressed EryCIII·EryCII (Fig. 3b) reveals
only one major component with a sedimentation
coefficient of 7.58 S, which, from a c(M) analysis,
corresponds to a molecular mass of 188 kDa.
Denaturing polyacrylamide gel analysis of purified
EryCIII·EryCII (Supplementary Fig. S3) reveals
bands of approximately equal intensity, suggesting
a 1:1 molar ratio of EryCIII·EryCII in the complex.
Taken together with the molecular masses of the8 10 12 14
Coefficient (S)
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CII (188 kDa)
Fig. 3. EryCII stabilizes the oligo-
meric state of EryCIII. Sedimenta-
tion velocity profiles, the residuals
after fitting and the c(S) distribution
for isolated EryCIII (a) and the
complex formed between EryCII
and EryCIII (b). The r.m.s.d. of the
fits and the recovered frictional co-
efficients were 0.005, 1.7 (a) and 0.03,
1.5 (b), respectively. The sedimenta-
tion coefficient distribution of EryCIII
reveals higher-order oligomers in
addition to the monomeric species
(M), which has a sedimentation
coefficient of 2.44 S, while that of the
EryCIII·EryCII complex consists of
a single dominant component at
7.58 S corresponding to a molecular
mass of 188 kDa (See also Fig. S3).
Table 1. Crystallographic data collection and refinement
statistics
Native Se-Met (peak)
Data collection
Space group P23 P23
Cell dimensions
a=b=c (Å) 141.9 143.0
Resolution (Å) 19.7–3.1 20.0–3.5
Rpim (%) 3.6 (27.5)
a 3.2 (14.0)
I/σI 14.5 (3.0) 21.7 (5.8)
Completeness (%) 99.4 (100) 99.6 (100)
Redundancy 7.2 (7.5) 11.8 (12)
Refinement
Resolution (Å) 3.1
No. of reflections 17,457
Rwork/Rfree 0.21/0.26
No. of atoms
Protein 5444
Average B-factor 93.7
r.m.s. deviations
Bond lengths (Å) 0.014
Bond angles (°) 1.862
Validation
Ramachandran favored/allowed (%) 94/100
Poor rotamers (%) 0.2
MolProbity score 2.1b
a Numbers in parentheses are for the highest-resolution shell.
b 99th percentile.
(a)
(c)(b)
-10 10kT/e
EryCII
EryCIII
Fig. 4. Assembly of the EryCIII·EryCII complex. The bio
arranged in an almost linear array (a). The EryCIII·EryCII in
homodimeric EryCIII·EryCIII interface is hydrophobic (d).
95EryCIII in Complex with EryCIIindividual proteins (48.1 and 40.7 kDa), the sedimen-
tation data are consistent with a complex containing
two molecules each of EryCIII and EryCII.
Structure of the EryCIII·EryCII complex
The structure of the EryCIII·EryCII complex was
solved at 3.1 Å using data derived from crystals of
both native and selenomethionine (Se-Met)-labeled
proteins. Data collection, phasing and refinement
statistics are summarized in Table 1. The asymmetric
unit is composed of an EryCIII·EryCII heterodimer,
and in agreement with the analytical ultracentrifu-
gation data, the biological unit is tetrameric consist-
ing of two EryCIII·EryCII heterodimers arranged in
an almost linear array (Fig. 4a). Analysis of the
EryCIII·EryCII tetramer by the PISA server18 reveals
that the total buried surface area is 8568 Å2. The
buried surface area for the EryCIII·EryCIII dimer
interface is 1497 Å2 and that for both EryCIII·EryCII
interfaces, 2787 Å2. The EryCIII·EryCII interface
(Fig. 4b and c) is predominantly composed of
electrostatic interactions between the N-terminal
helix of EryCII, which occupies a groove formed by
three helices [α-3/(3a), α-4a and α-6a] of EryCIII.
This interface is stabilized by hydrogen bonds
between the following residue pairs (EryCII·EryCIII):(d)
EryCIII
EryCII
logical unit is composed of two EryCIII·EryCII dimers
terface is predominantly electrostatic (b and c), while the
96 EryCIII in Complex with EryCIIR26:E210, R31:A125, R31:S128, Q34:E203, Q34:P200,
R37:E198, Y43:A86, R77:D89, R77:A86, R77:H85,
R110:D81, L201:E203 (peptide backbone), E107:H85
and R364:H196 (peptide backbone). The EryCIII·Er-
yCIII homodimer interface (Fig. 4d) is primarily
hydrophobic but is stabilized by hydrogen bonds
between A424:A46 (peptide backbone), H330:T69,
V257:A70 (peptide backbone), A70:S255 (peptide
backbone) and R52:H330.
Structure of EryCIII
The EryCIII monomer consists of two globular
domains (S19–G245 and R269–G436) connected
by a 23-residue (M246–R268) linker, and both are
stabilized by interactions with the C-terminal helix
(Fig. 5a). Through the use of the VAST19 and
PDBeFOLD20 servers, close structural homologues
of EryCIII were identified including CalG3,10
[Protein Data Bank (PDB) code 3D0R], UrdGT29
(PDB code 2P6P) and the oleandomycin GTs OleI
and OleD11 (PDB codes 2IYA and 2IYF). Of these,
CalG3 is the closest homologue, and it structurallyB
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Fig. 5. Topology and structural features of EryCIII and Ery
2P6P) reveals common features of the GT-B family of GTs. R
within rectangles. (b) Residues on EryCIII predicted to be invo
red and blue, respectively. The A″ and B helices of EryCII intera
(c) Superposition of EryCII and the cytochrome P450 homol
EryCII. Although EryCII lacks the heme moiety, the long I he
binding pocket are conserved. (d) Distribution of crystallograp
values are observed for residues distal to the A″ helix of EryCaligns with EryCIII for 318 residues with 32%
sequence identity and an r.m.s.d. of 2.06 Å (Dali
Z-score, 37; r.m.s.d., 3.0 Å). Mittler et al. have noted
the very strong conservation of ligand binding
modes in six related GTs and have successfully
designed changes in the active site of the land-
omycin O-glycosyltransferase LanGT2 to create an
aryl-C-glycosyltransferase.9,21 We have used a
similar approach to identify active-site interactions
in EryCIII. As in all these other GT-B GTs, the donor
sugar binding site of EryCIII is located in the
C-terminal domain. Figure 5a shows the structure
of EryCIII superimposed on that of UrdGT2 (PDB
code 2P6P), and Supplementary Fig. S4b shows a
structure-based sequence alignment of EryCIII with
several structural homologues, some with bound
ligands.10,11 F326 of EryCIII aligns with W312
(OleI), W289 (OleD) and W285 of CalG2. In OleI
and OleD, the benzyl moiety of the tryptophan side
chain stacks against the uracil base.11 Similarly, the
aromatic side chain of W285 in CalG2 stacks against
the thymidine base, and an analogous interaction
is expected between the nucleotide substrate TDP-AD
A˝
B
(b)
(d)
yCII EryCIII
A˝
2-fold
α-6a
α-3/3a
CII. (a) Superposition of EryCIII and UrdGT2 (PDB code
egions containing the Rossmann-like domains are shown
lved in donor (d) and acceptor (a) binding are depicted in
ct with helices that are close to the acceptor site of EryCIII.
ogue CYP125 (PDB code 2XC3) showing the A″ helix of
lix and others (J, K, K′ and L) in the vicinity of the heme-
hic B-factors for the EryCIII·EryCII complex. High B-factor
II (See also Fig. S5).
97EryCIII in Complex with EryCIIdesosamine and F326 of EryCIII. G275 of EryCIII is
conserved in the GTs, and the equivalent residue in
CalG2 (G236) interacts with the pyrophosphate
oxygen atoms O2A, O3A and also C5M on
thymidine. The carbonyl oxygen and amide nitro-
gen of V286 in CalG2 are involved in van der
Waals and hydrogen bond interactions with thy-
midine. H342 in EryCIII is absolutely conserved in
the GTs shown (Supplementary Fig. S4b), and G344
and G346 are also strongly conserved. In CalG2,
the imidazole moiety of the equivalent histidine
residue (H301) and the glycine residues, G303 and
G305, are involved in pyrophosphate recognition.
T306 of CalG2 participates in phosphate (PA, O2A)
and sugar (C2′) recognition, while E309 is involved
in sugar recognition only. In EryCIII, S347 and T350
correspond to T306 and E309 of CalG2, respectively.
In the difference density map of the refined
EryCIII·EryCII complex, residual density roughly
the size of a sugar could be observed in the putative
catalytic pocket, which is likely to be due to the
binding of a small ligand that originates from the
E. coli expression host. The density was not
sufficiently clear to unambiguously identify the
ligand; however, this observation does suggest that
the pocket can accommodate a substrate.
The structure of the oleandomycin GT OleD was
obtained in complex with both UDP and erythro-
mycin A,11 and this similarly allowed us to identify
residues in EryCIII that likely interact with the
substrate 3-α-mycarosyl erythronlide B (Fig. 5b and
Supplementary Fig. S4a). There are two highly
conserved residues in OleD that interact with
erythromycin: H19 and D329, which align with H33
and D366, respectively, in EryCIII. The imidazole
nitrogen of H19 is involved in hydrogen bond
interactions with O8 of desosamine. Additionally,
van der Waals interactions exist between H19 and
C23/C29 of the desosamine moiety of erythro-
mycin A. Before the attachment of desosamine, H33
is therefore not expected to be involved in interac-
tions with the scaffold. D329 of OleD is, however,
involved in mycarose recognition via its interaction
with C19, and this is expected to be preserved by
D366 of EryCIII. The following residues in EryCIII
are also expected to be involved in acceptor substrate
binding by interacting with the polyketide scaffold:
M127 (C21), S128 (O11), L132 (C22,C33), E151 (C35),
G174 (C31), P175 (C37), D176 (C37), Q183 (C37), V222
(C34) and V223 (O13) (Fig. 5b).
Structure of EryCII
Structural comparison19,20 confirms that EryCII is
homologous to cytochrome P450, and the two closest
structural homologues are the putative cytochrome
P450 from Mycobacterium tuberculosis, CYP125 (PDB
code 2XC3), which aligns for 264 residues with an
r.m.s.d. of 2.38 Å and has 18% sequence identity, andcytochrome P450 CypX22 from Bacillus subtilis (PDB
code 3NC3), which aligns for 254 residues with 20%
sequence identity and an r.m.s.d. of 2.38 Å (Dali
Z-score, 25; r.m.s.d., 2.7 Å). As expected for EryCII—
and indeed themacrolide auxiliary proteins generally
—the conserved cysteine is absent (Supplementary
Fig. S5); thus, they are not active P450 enzymes.
Structure-based alignment of EryCII and P450Cyp125
(PDB code 2XC3) is shown in Fig. 5c (see also
Supplementary Fig. S5). These representations reveal
that EryCII differs significantly from authentic P450
enzymes in possessing a long helix before the
canonical A′ helix found in P450terp
23 (Cyp108 from
Pseudomonas sp.). This helix (A″) provides the main
interaction surface with EryCIII in the EryCIII·EryCII
complex and is expected to be present in other
EryCII homologues. EryCII lacks the C and C′
helices, and parts of the G and H helices are missing.
However, the I, J, K, K′ and L helices and the β-
sheets in the C-terminal half are very well conserved
(Supplementary Fig. S5). The portion of EryCII that
corresponds to the binding site for heme cofactor and
substrate in a P450 enzyme shows elevated B-factors
(Fig. 5d), suggesting significant conformational
mobility in this region.Discussion
The discovery that the protein DesVIII from the
pikromycin biosynthetic pathway is an activator of
the GT DesVII12 has triggered considerable interest
in the mechanism of activation primarily because
such glycosylation steps are crucial to antibiotic
function and, if understood, should accelerate
knowledge-based engineering of the attachment of
novel deoxysugars to such templates. The role of
proteins from the DesVIII/EryCII family could
include effects on both folding and catalysis. Earlier
studies of the in vitro properties of recombinant
EryCIII encountered experimental difficulties in
obtaining homogenous active enzyme16 but suc-
ceeded in confirming the ability of EryCII to enhance
the desosaminyltransferase activity of this enzyme,
as found for the DesVII/DesVIII pair. The authors of
that study proposed that a stable complex between
EryCIII and EryCII does not exist, based on their
observation that EryCIII temporarily exposed to
EryCII acquired and maintained full enzymatic
activity.13 Reinvestigation of the in vitro activation
of DesVII by DesVIII15 has shown, in contrast, that
co-expression of these proteins resulted in a stable
1:1 complex, which could not be formed by simply
mixing separately the purified components. Activity
was also seen after temporarily exposing DesVII to
DesVIII, and this was proposed to arise from residual
contaminating amounts of activating DesVIII.
In the present work, we have developed a new
expression system that utilizes co-expressed
98 EryCIII in Complex with EryCIIchaperones derived from S. coelicolor17 to facilitate
the individual expression of EryCIII and EryCII and
their co-expression. When co-expressed, EryCII and
EryCIII form a tight complex that remains intact
following nickel affinity, ion-exchange and size-
exclusion chromatography. The stoichiometry of the
purified EryCIII·EryCII complex in solution, deter-
mined from sedimentation velocity data, is α2β2,
and this agrees exactly with the stoichiometry found
in the crystal structure, where the EryCIII·EryCII
complex appears as a dimer of heterodimers. On the
basis of its retention volume during size-exclusion
chromatography, the DesVII/DesVIII complex was
previously reported to be a trimer of heterodimers
(α3β3),
15 but given the elongated shape of the
complex, it is likely that this estimate was in error
and other GT-auxiliary protein pairs are also α2β2
tetrameric complexes when correctly assembled.
Before the role of DesVIII was established,12 it was
known that the function of EryCII could be replaced
in vivo by OleP1 from the oleandomycin pathway,24
and since then, many examples of such crosstalk
have been demonstrated.13,15,25–28 Thus, AknT,
which has 26% sequence identity to EryCII, activates
EryCIII, and EryCII, OleP1 and DnrQ, which share,
respectively, 34%, 32% and 38% sequence identity
with DesVIII, activate DesVII26 at least to some
extent. However, TylMIII, which is 36% identical
with DesVIII, does not activate DesVII,15,26 and the
angolosaminyltransferase activator AngMIII, which
is 45% identical with TylMIII, does not activate
TylMII. 29 Since the A″ helix on EryCII is a
prominent part of the interface with EryCIII, we
made an initial attempt to correlate the ability of a
given activator to activate a non-cognate GT with
amino acid differences in this region. We note that
there are potentially some discriminating substitu-
tions at the interface: D23 in DesVIII (R26 in EryCIII)
is conserved in AknT and DnrQ (D15 and D13) but
is replaced by the hydrophobic L23 in TylMIII.
Similarly, L31 in DesVIII is conserved in AknT and
DnrQ (L23, L21).
The hydrodynamic data for co-expressed Ery-
CIII·EryCII strongly support the notion that one
function of the auxiliary proteins is to stabilize the
fold and quaternary structure of its partner GT.
Additionally, the finding that the GT activity of
EryCIII, expressed on its own, is almost completely
rescued by the addition of soluble EryCII suggests
that the auxiliary protein is able to induce aEryCII
TDP-desosamine
MycEB
EryCIII
mains of EryCIII are such that the acceptor (MycEB) and dono
EryCII binding engages these sites and allows efficient glycos
that substrate binding to the enzyme may not be totally depecatalytically active structure in EryCIII. The Ery-
CIII·EryCII dimer interface is formed by the N-
terminal A″ helix of EryCII and helices exclusively in
the N-terminal domain of EryCIII, which contains
the acceptor binding site. Although this interface
does not have direct interactions with the inferred
acceptor binding site, it is an attractive hypothesis
that allosteric binding of EryCII not only stabilizes
the overall fold of the GT but also specifically
modulates the structure and the dynamics of the
acceptor site, thus promoting catalysis. There are
several precedents for such a modulation of enzy-
matic activity, both by small molecules and by
proteins. In a recent study of cAMP activation of
protein kinase A, for example, the nucleotide was
demonstrated to couple the two lobes of the enzyme
by binding to a specific set of residues, the C-spine
residues, which are disengaged in the absence of
nucleotide.30 Nucleotide binding completes the
spine and allows subsequent ligand binding and
catalysis. Binding of EryCII to the N-terminal
acceptor domain of EryCIII (Fig. 6) may likewise
trigger a closer association with the C-terminal
sugar-nucleotide binding domain and the correct
juxtaposition of the acceptor and donor sites of
EryCIII. An example of protein:protein interaction
boosting enzymatic activity of one of the partners is
provided by the recently solved crystal structure of a
complex between the intracellular chorismate mu-
tase of M. tuberculosis and the 3-deoxy-D-arabino-
heptulosonate-7-phosphate synthase from the same
pathway.31 In the complex, mutase homodimers
flank a central core of synthase subunits. The
synthase does not contribute directly to the mutase
active site, but there are specific movements (by
approximately 10 Å) of key mutase residues upon
complex formation. This creates a conformation that
favors catalysis, lowering Km for chorismate by 30-
fold and increasing kcat by 4-fold. The rationale
proposed for this interaction is that it allows the
regulation of chorismate mutase by feedback mech-
anisms. It is tempting to speculate that the complex
of EryCIII with its activator protein might form part
of an analogous regulatory system.
Our work reveals an unusual quaternary struc-
ture for the complex of a GT and its auxiliary
partner. We suggest that the heterotypic interac-
tions of enzyme and partner allosterically activate
the catalytic activity. In the case of EryCII, the fold is
an elaboration of a P450-like structure and is likelyFig. 6. Model of a possible mech-
anism by which EryCII activates
EryCIII. In the absence of EryCII,
the dynamics of the N-terminal
(green) and C-terminal (grey) do-
r (TDP-desosamine) sites are predominantly disengaged.
yltransfer. The low activity of some isolated GTs suggests
ndent on the presence of its auxiliary partner.
99EryCIII in Complex with EryCIIto have originated from a peroxidase-like ancestor.
Having lost the heme group in the central core, the
protein may be more conformationally dynamic, as
suggested by the distribution of crystallographic
thermal disorder parameters. However, it serves as
a scaffold that presents a new α-helix that forms an
extensive contact surface with the EryCIII partner
and which likely affects the organization of that
subunit's active site. Other GTs that share the
requirement for auxiliary proteins are likely to
have a similar mode of activating interaction.Materials and Methods
The generation of plasmids for the expression of EryCIII
and EryCII and the methods used to purify the resulting
proteins are detailed in Supplementary Experimental
Procedures. Cell pellets from 500-ml cultures were
resuspended in 5 ml of a solution containing 50 mM
sodium phosphate, 5% v/v glycerol and 1 mM DTT,
pH 8.0, and sonicated (Mixonix-ultrasonic XL2020). The
cellular debriswas removed by centrifugation, and the total
protein concentration was measured using the Bradford
assay32 with bovine serum albumin as standard. Samples
were concentrated to 5–6.5 mg/ml and used for activity
assays without further purification. Purified proteins for
activity assayswere prepared as abovewith the omission of
2 mMDTT in the lysis buffer. The samples were loaded by
gravity flow onto a 20-ml Econo-Pac chromatography
column (Bio-Rad) containing 3 ml of Ni-NTA resin
(Qiagen) previously equilibrated with 10 ml of a solution
containing 50mM sodium phosphate, 300 ml NaCl and 5%
v/v glycerol, pH 8.0 (Buffer A) The resin was washed with
8 ml Buffer A followed by two washes with 8 ml Buffer A
containing 20 and 35 mM imidazole, respectively. Protein
was eluted with 5 ml Buffer A containing 150 mM
imidazole. The eluted proteins were analyzed by SDS-
PAGE andDTTwas added to a concentration of 1 mM and
the samples were used directly for activity assays.
Activity assays
Activity assays using cell-free extracts were performed
in 50 mM phosphate buffer, pH 8.0, containing 1 mMDTT
and 5% glycerol, as these are the optimal conditions.16 The
reaction mixture contained 20 μg TDP-D-desosamine (2),
10 μg MycEB (1) and a protein concentration of 6 mg/ml
in a total volume of 6 ml. Protein concentrations were
0.05 mg/ml (EryCII and DesVIII), 0.56 mg/ml (EryCIII)
and 0.14 mg/ml for co-purified EryCII·EryCIII. When
combining EryCIII with EryCII or DesVIII, the final
reaction volume was 10 ml. Reactions were incubated at
25 °C for 8–12 h, and 100 μl of 5 N NaOH was added if
required. The reactions were extracted with 1 volume of
ethyl acetate, and the organic phase was recovered.
Solvent was evaporated using a nitrogen stream, and the
residue was resuspended in 200 μl methanol. The identity
of erythromycin D (3) (703.45 g/mol) was confirmed using
LC-MS on a Finnigan MAT LCQ equipped with an
electrospray ionization-MS detector, by comparison with
an authentic reference standard. Chromatographic sepa-ration was performed using a Phenomenex Synergy polar
RP microbore column at a flow rate of 0.3 ml/min, with
solvents A, H2O and 0.1% trifluoroacetic acid, and B,
MeCN and 0.1% trifluoroacetic acid. The HPLC program
was as follows: 100% solvent A for 3 min followed by a
linear gradient from 0% to 100% solvent B in 27 min and,
finally, 100% solvent B for 5 min. Data processing was
performed using Xcalibur (Thermo Scientific).
Analytical ultracentrifugation
Sedimentation velocity experiments were performed
using a Beckman Optima XL-A analytical ultracentrifuge
equipped with absorbance and interference optics. A
solution (400 μl) of EryCIII (4.4 mg/ml) in 10 mM sodium
phosphate, 2 mM DTT and a complex of EryCIII·EryCII in
2 mM DTT were placed in the sample compartment of an
epon double-sector centerpiece, and 405 μl of the same
solution without protein was placed in the reference
compartment. The samples were centrifuged at 293 K
and 50,000 r.p.m. (201,600g) using an An60-Ti rotor. Scans
were acquired at time intervals of 1.5 min. The calculated
partial specific volumes of 0.734 and 0.728 mg/ml for
EryCIII and EryCII were obtained from their respective
amino acid compositions using SEDNTERP,33 and these
were used to calculate the weight-average partial specific
volume of the EryCIII·EryCII complex. c(S) and c(M)
distributions were calculated using the program SEDFIT.34
Crystallization and structure determination
Crystals of the EryCIII·EryCII complex were obtained
using the hanging-drop vapor diffusion method at room
temperature and a protein concentration of 3–5 mg/ml.
The well solution contained 4 M sodium formate and was
mixed in a 1:1 ratio with protein solution. Crystals had
cubic morphology and were flash frozen in liquid
nitrogen. Native data sets were collected at ID-14.1
(European Synchrotron Radiation Facility, Grenoble),
and Se-Met data sets were collected at the Diamond
Light Source, (Didcot, UK). Data reduction and scaling
were performed using XDS35 and Scala.36 Initial phases
from the Se-Met data were obtained using autoSHARP,37
and a partial (30%) model of EryCIII was obtained using
Buccaneer.38 Further rounds of manual model building
and refinement were performed using Coot39 and
Buster,40 and final refinement was done using PHENIX.41
Accession numbers
The refined coordinates and structure factors have been
deposited in the PDB with accession number 2YJN.Acknowledgements
We thank the staff at the European Synchrotron
Radiation Facility and Diamond Light Source for
use of facilities and helpful advice during data
collection. Work in the Leadlay and Gay groups
100 EryCIII in Complex with EryCIIwas supported by the Biotechnology and Biological
Sciences Research Council, (BB/F023111/1 and
BB/G002797/1 respectively) and work in the Luisi
group was supported by the Wellcome Trust
(076846/Z/05/A). M-JF was the recipient of a
postdoctoral fellowship from the Spanish Ministry
of Science.
Supplementary Data
Supplementary data associated with this article
can be found, in the online version, at doi:10.1016/
j.jmb.2011.10.036
References
1. Weymouth-Wilson, A. C. (1997). The role of carbohy-
drates in biologically active natural products. Nat.
Prod. Rep. 14, 99–110.
2. Salas, A. J. & Mendez, C. (2007). Engineering the
glycosylation of natural products in actinomyces.
Trends Microbiol. 15, 219–232.
3. Thibodeaux, C. J., Melançon, C. E. & Liu, H. W. (2008).
Natural-product sugar biosynthesis and enzymatic
glycodiversification. Angew. Chem., Int. Ed. Engl. 47,
9814–9859.
4. Mulichak, A. M., Losey, H. C., Walsh, C. T. & Garavito,
R. M. (2001). Structure of the UDP-glucosyltransferase
GtfB that modifies the heptapeptide aglycone in the
biosynthesis of vancomycin group antibiotics. Structure,
9, 547–557.
5. Mulichak, A. M., Losey, H. C., Lu, W., Wawrzak, Z.,
Walsh, C. T. & Garavito, R. M. (2003). Structure of
the TDP-epi-vancosaminyltransferase GtfA from the
chloroeremomycin biosynthetic pathway. Proc. Natl
Acad. Sci. USA, 100, 9238–9243.
6. Mulichak, A. M., Lu, W., Losey, H. C., Walsh, C. T. &
Garavito, R. M. (2004). Crystal structure of vancosa-
minyltransferase GtfD from the vancomycin biosyn-
thetic pathway: interactions with acceptor and
nucleotide ligands. Biochemistry, 43, 5170–5180.
7. Truman, A. W., Dias, M. V. B., Wu, S., Blundell,
T. L., Huang, F. & Spencer, J. B. (2009). Chimeric
glycosyltransferases for the generation of hybrid
glycopeptides. Chem. Biol. 16, 676–685.
8. Martinez-Fleites, C., Korczynska, J. E., Davies, G. J.,
Cope, M. J., Turkenburg, J. P. & Taylor, E. J. (2009).
The crystal structure of a family GH25 lysozyme
from Bacillus anthracis implies a neighboring-group
catalytic mechanism with retention of anomeric
configuration. Carbohydr. Res. 344, 1753–1757.
9. Mittler, M., Bechthold, A. & Schulz, G. E. (2007).
Structure and action of the C–C bond-forming
glycosyltransferase UrdGT2 involved in the biosyn-
thesis of the antibiotic urdamycin. J. Mol. Biol. 372,
67–76.
10. Zhang, C., Bitto, E., Goff, R. D., Singh, S., Bingman,
C. A., Griffith, B. R. et al. (2008). Biochemical and
structural insights of the early glycosylation steps in
calicheamicin biosynthesis. Chem. Biol. 15, 842–853.
11. Bolam, D. N., Roberts, S., Proctor, M. R., Turkenburg,
J. P., Dodson, E. J., Martinez-Fleites, C. et al. (2007).The crystal structure of two macrolide glycosyltrans-
ferases provides a blueprint for host cell antibiotic
immunity. Proc. Natl Acad. Sci. USA, 104, 5336–5341.
12. Borisova, S., Zhao, L., III, C. M., Kao, C. & Liu, H.
(2004). Characterization of the glycosyltransferase
activity of DesVII: analysis of and implications for
the biosynthesis of macrolide antibiotics. J. Am. Chem.
Soc. 126, 6534–6535.
13. Yuan, Y., Chung, H. S., Leimkuhler, C., Walsh, C. T.,
Kahne, D. & Walker, S. (2005). In vitro reconstitution
of EryCIII activity for the preparation of unnatural
macrolides. J. Am. Chem. Soc. 127, 14128–14129.
14. Lu, W., Leimkuhler, C., Gatto, G. J., Kruger, R. G.,
Oberthür, M., Kahne, D. & Walsh, C. T. (2005). AknT
is an activating protein for the glycosyltransferase
AknS in L-aminodeoxysugar transfer to the aglycone
of aclacinomycin A. Chem. Biol. 12, 527–534.
15. Borisova, S. A. & Liu, H. W. (2010). Characterization
of glycosyltransferase DesVII and its auxiliary partner
protein DesVIII in the methymycin/pikromycin bio-
synthetic pathway. Biochemistry, 49, 8071–8084.
16. Lee, H. Y., Chung, H. S., Hang, C., Khosla, C., Walsh,
C. T., Kahne, D. & Walker, S. (2004). Reconstitution
and characterization of a new desosaminyl transfer-
ase, EryCIII, from the erythromycin biosynthetic
pathway. J. Am. Chem. Soc. 126, 9924–9925.
17. Betancor, L., Fernández, M. J., Weissman, K. J. &
Leadlay, P. F. (2008). Improved catalytic activity of a
purified multienzyme from a modular polyketide
synthase after coexpression with Streptomyces chaper-
onins in Escherichia coli. Chembiochem, 9, 2962–2966.
18. Krissinel, E. & Henrick, K. (2007). Inference of
macromolecular assemblies from crystalline state.
J. Mol. Biol. 372, 774–797.
19. Gibrat, J. F., Madej, T. & Bryant, S. H. (1996).
Surprising similarities in structure comparison. Curr.
Opin. Struct. Biol. 6, 377–385.
20. Krissinel, E. & Henrick, K. (2004). Secondary-structure
matching (SSM), a new tool for fast protein structure
alignment in three dimensions. Acta Crystallogr., Sect.
D: Biol. Crystallogr. 60, 2256–2268.
21. Härle, J., Günther, S., Lauinger, B., Weber, M.,
Kammerer, B., Zechel, D. L. et al. (2011). Rational
design of an aryl-C-glycoside catalyst from a natural
product O-glycosyltransferase. Chem. Biol. 18, 520–530.
22. Cryle, M. J., Bell, S. G. & Schlichting, I. (2010).
Structural and biochemical characterization of the
cytochrome P450 CypX (CYP134A1) from Bacillus
subtilis: a cyclo-L-leucyl-L-leucyl dipeptide oxidase.
Biochemistry, 49, 7282–7296.
23. Hasemann, C. A., Kurumbail, R. G., Boddupalli, S. S.,
Peterson, J. A. & Deisenhofer, J. (1995). Structure and
function of cytochromes P450: a comparative analysis
of three crystal structures. Structure, 3, 41–62.
24. Doumith, M., Legrand, R., Lang, C., Salas, J. A. &
Raynal, M. C. (1999). Interspecies complementation in
Saccharopolyspora erythraea: elucidation of the function
of oleP1, oleG1 and oleG2 from the oleandomycin
biosynthetic gene cluster of Streptomyces antibioticus
and generation of new erythromycin derivatives.Mol.
Microbiol. 34, 1039–1048.
25. Melançon, C. E., Takahashi, H. & Liu, H. W.
(2004). Characterization of TylM3/TylM2 and MycC/
MycB pairs required for efficient glycosyltransfer in
101EryCIII in Complex with EryCIImacrolide antibiotic biosynthesis. J. Am. Chem. Soc.
126, 16726–16727.
26. Hong, J. S. J., Park, S. J., Parajuli, N., Park, S. R., Koh,
H. S., Jung, W. S. et al. (2007). Functional analysis of
DesVIII homologues involved in glycosylation of
macrolide antibiotics by interspecies complementa-
tion. Gene, 386, 123–130.
27. Useglio, M., Peirú, S., Rodríguez, E., Labadie, G. R.,
Carney, J. R. & Gramajo, H. (2010). TDP-L-megosa-
mine biosynthesis pathway elucidation and mega-
lomicin a production in Escherichia coli. Appl. Environ.
Microbiol. 76, 3869–3877.
28. Nguyen, H. C., Karray, F., Lautru, S., Gagnat, J.,
Lebrihi, A., Huynh, T. D. H. & Pernodet, J. L. (2010).
Glycosylation steps during spiramycin biosynthesis in
Streptomyces ambofaciens: involvement of three glyco-
syltransferases and their interplay with two auxiliary
proteins. Antimicrob. Agents Chemother. 54, 2830–2839.
29. Schell, U., Haydock, S. F., Kaja, A. L., Carletti, I.,
Lill, R. E., Read, E. et al. (2008). Engineered
biosynthesis of hybrid macrolide polyketides con-
taining D-angolosamine and D-mycaminose moieties.
Org. Biomol. Chem. 6, 3315–3327.
30. Masterson, L. R., Cheng, C., Yu, T., Tonelli, M.,
Kornev, A., Taylor, S. S. & Veglia, G. (2010). Dynamics
connect substrate recognition to catalysis in protein
kinase A. Nat. Chem. Biol. 6, 821–828.
31. Sasso, S., Okvist, M., Roderer, K., Gamper, M.,
Codoni, G., Krengel, U. & Kast, P. (2009). Structure
and function of a complex between chorismate mutase
and DAHP synthase: efficiency boost for the junior
partner. EMBO J. 28, 2128–2142.
32. Zor, T. & Selinger, Z. (1996). Linearization of the
Bradford protein assay increases its sensitivity:theoretical and experimental studies. Anal. Biochem.
236, 302–308.
33. Laue, T. M., Shah, B. D., Ridgeway, T. M. &
Pelletier, S. L. (1992). Computer-aided interpretation
of analytical sedimentation data for proteins. In
Analytical Ultracentrifugation in Biochemistry and
Polymer Science (Harding, S. E., Rowe, A. J. &
Horton, J. C., eds), pp. 90–125, Royal Society of
Chemistry, Cambridge, UK.
34. Schuck, P. (2000). Size-distribution analysis of
macromolecules by sedimentation velocity ultracen-
trifugation and Lamm equation modeling. Biophys. J.
78, 1606–1619.
35. Kabsch, W. (2010). XDS. Acta Crystallogr., Sect. D: Biol.
Crystallogr. 66, 125–132.
36. Evans, P. (2006). Scaling and assessment of data
quality. Acta Crystallogr., Sect. D: Biol. Crystallogr. 62,
72–82.
37. Vonrhein, C., Blanc, E., Roversi, P. & Bricogne, G.
(2007). Automated structure solution with auto-
SHARP. Methods Mol. Biol. 364, 215–230.
38. Cowtan, K. (2006). The buccaneer software for auto-
mated model building. 1. Tracing protein chains. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 62, 1002–1011.
39. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K.
(2010). Features and development of Coot. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 66, 486–501.
40. Brigone, G., Blanc, E., Brandl, M., Flensburg, C.,
Keller, P., Paciorek, P. et al. (2008). Buster. 2.8.0.
41. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B.,
Davis, I. W., Echols, N. et al. (2010). Phenix: a
comprehensive Python-based system for macromo-
lecular structure solution. Acta Crystallogr., Sect. D:
Biol. Crystallogr. 66, 213–221.
